{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:55:00Z","timestamp":1792000500930,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Proteom"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Transthyretin (TTR), an abundant protein in cerebrospinal fluid (CSF), contains a free, oxidation-prone cysteine residue that gives rise to TTR isoforms. These isoforms may reflect conditions <jats:italic>in vivo<\/jats:italic>. Since increased oxidative stress has been linked to neurodegenerative disorders such as Alzheimer\u2019s disease (AD) it is of interest to characterize CSF-TTR isoform distribution in AD patients and controls. Here, TTR isoforms are profiled directly from CSF by an optimized immunoaffinity-mass spectrometry method in 76 samples from patients with AD (n = 37), mild cognitive impairment (MCI, n = 17)), and normal pressure hydrocephalus (NPH, n = 15), as well as healthy controls (HC, n = 7). Fractions of three specific oxidative modifications (S-cysteinylation, S-cysteinylglycinylation, and S-glutathionylation) were quantitated relative to the total TTR protein. Results were correlated with diagnostic information and with levels of CSF AD biomarkers tau, phosphorylated tau, and amyloid \u03b2<jats:sub>1-42<\/jats:sub> peptide.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Preliminary data highlighted the high risk of artifactual TTR modification due to <jats:italic>ex vivo<\/jats:italic> oxidation and thus the samples for this study were all collected using strict and uniform guidelines. The results show that TTR is significantly more modified on Cys(10) in the AD and MCI groups than in controls (NPH and HC) (p \u2264 0.0012). Furthermore, the NPH group, while having normal TTR isoform distribution, had significantly decreased amyloid \u03b2 peptide but normal tau values. No obvious correlations between levels of routine CSF biomarkers for AD and the degree of TTR modification were found.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>AD and MCI patients display a significantly higher fraction of oxidatively modified TTR in CSF than the control groups of NPH patients and HC. Quantitation of CSF-TTR isoforms thus may provide diagnostic information in patients with dementia symptoms but this should be explored in larger studies including prospective studies of MCI patients. The development of methods for simple, robust, and reproducible inhibition of <jats:italic>in vitro<\/jats:italic> oxidation during CSF sampling and sample handling is highly warranted. In addition to the diagnostic information the possibility of using TTR as a CSF oxymeter is of potential value in studies monitoring disease activity and developing new drugs for neurodegenerative diseases.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1559-0275-11-12","type":"journal-article","created":{"date-parts":[[2014,3,29]],"date-time":"2014-03-29T10:01:33Z","timestamp":1396087293000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Distinct transthyretin oxidation isoform profile in spinal fluid from patients with Alzheimer\u2019s disease and mild cognitive impairment"],"prefix":"10.1186","volume":"11","author":[{"given":"Keld","family":"Poulsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna MC","family":"Bahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja H","family":"Simonsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen G","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels HH","family":"Heegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,29]]},"reference":[{"issue":"3","key":"56_CR1","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jalz.2007.04.381","volume":"3","author":"R Brookmeyer","year":"2007","unstructured":"Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM: Forecasting the global burden of Alzheimer\u2019s disease. Alzheimers Dement. 2007, 3 (3): 186-191. 10.1016\/j.jalz.2007.04.381","journal-title":"Alzheimers Dement"},{"issue":"9533","key":"56_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H: Alzheimer\u2019s disease. Lancet. 2006, 368 (9533): 387-403. 10.1016\/S0140-6736(06)69113-7","journal-title":"Lancet"},{"issue":"3","key":"56_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow K, Hampel H, Weiner M, Zetterberg H: Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010, 6 (3): 131-144. 10.1038\/nrneurol.2010.4","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"56_CR4","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/S1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O\u2019Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P: Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007, 6 (8): 734-746. 10.1016\/S1474-4422(07)70178-3","journal-title":"Lancet Neurol"},{"issue":"2","key":"56_CR5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.31887\/DCNS.2009.11.2\/bdubois","volume":"11","author":"B Dubois","year":"2009","unstructured":"Dubois B, Picard G, Sarazin M: Early detection of Alzheimer\u2019s disease: new diagnostic criteria. Dialogues Clin Neurosci. 2009, 11 (2): 135-139.","journal-title":"Dialogues Clin Neurosci"},{"key":"56_CR6","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1749-6632.1996.tb39057.x","volume":"786","author":"K Hensley","year":"1996","unstructured":"Hensley K, Butterfield DA, Hall N, Cole P, Subramaniam R, Mark R, Mattson MO, Markesbery WR, Harris ME, Aksenov M, Aksenova M, Wu JF, Carney JM: Reactive oxygen species as causal agents in the neurotoxicity of the Alzheimer\u2019s disease-associated amyloid beta peptide. Ann N Y Acad Sci. 1996, 786: 120-134. 10.1111\/j.1749-6632.1996.tb39057.x","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"56_CR7","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1021\/tx700210j","volume":"21","author":"LM Sayre","year":"2008","unstructured":"Sayre LM, Perry G, Smith MA: Oxidative stress and neurotoxicity. Chem Res Toxicol. 2008, 21 (1): 172-188. 10.1021\/tx700210j","journal-title":"Chem Res Toxicol"},{"issue":"14","key":"56_CR8","first-page":"4572","volume":"26","author":"T Pettersson","year":"1987","unstructured":"Pettersson T, Carlstrom A, Jornvall H: Different types of microheterogeneity of human thyroxine-binding prealbumin. Can J Neurol Sci. 1987, 26 (14): 4572-4583.","journal-title":"Can J Neurol Sci"},{"issue":"7","key":"56_CR9","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1002\/pmic.200500285","volume":"6","author":"A Biroccio","year":"2006","unstructured":"Biroccio A, Del Boccio P, Panella M, Bernardini S, Di Ilio C, Gambi D, Stanzione P, Sacchetta P, Bernardi G, Martorana A, Federici G, Stefani A, Urbani A: Differential post-translational modifications of transthyretin in Alzheimer\u2019s disease: a study of the cerebral spinal fluid. Proteomics. 2006, 6 (7): 2305-2313. 10.1002\/pmic.200500285","journal-title":"Proteomics"},{"issue":"1","key":"56_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejphar.2006.06.026","volume":"545","author":"DA Butterfield","year":"2006","unstructured":"Butterfield DA, Perluigi M, Sultana R: Oxidative stress in Alzheimer\u2019s disease brain: new insights from redox proteomics. Eur J Pharmacol. 2006, 545 (1): 39-50. 10.1016\/j.ejphar.2006.06.026","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"56_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00401-009-0517-0","volume":"118","author":"R Sultana","year":"2009","unstructured":"Sultana R, Perluigi M, Butterfield DA: Oxidatively modified proteins in Alzheimer\u2019s disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis. Acta Neuropathol. 2009, 118 (1): 131-150. 10.1007\/s00401-009-0517-0","journal-title":"Acta Neuropathol"},{"issue":"11","key":"56_CR12","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.neurobiolaging.2005.09.021","volume":"27","author":"R Sultana","year":"2006","unstructured":"Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Merchant M, Markesbery WR, Butterfield DA: Redox proteomics identification of oxidized proteins in Alzheimer\u2019s disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging. 2006, 27 (11): 1564-1576. 10.1016\/j.neurobiolaging.2005.09.021","journal-title":"Neurobiol Aging"},{"issue":"5","key":"56_CR13","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/00001756-200204160-00015","volume":"13","author":"P Davidsson","year":"2002","unstructured":"Davidsson P, Westman-Brinkmalm A, Nilsson CL, Lindbjer M, Paulson L, Andreasen N, Sjogren M, Blennow K: Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport. 2002, 13 (5): 611-615. 10.1097\/00001756-200204160-00015","journal-title":"Neuroreport"},{"issue":"2","key":"56_CR14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3233\/JAD-2009-0966","volume":"16","author":"SF Hansson","year":"2009","unstructured":"Hansson SF, Andreasson U, Wall M, Skoog I, Andreasen N, Wallin A, Zetterberg H, Blennow K: Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer\u2019s disease patients. J Alzheimers Dis. 2009, 16 (2): 389-397.","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"56_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1600-0404.1988.tb03687.x","volume":"78","author":"H Riisoen","year":"1988","unstructured":"Riisoen H: Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer\u2019s disease. Acta Neurol Scand. 1988, 78 (6): 455-459. 10.1111\/j.1600-0404.1988.tb03687.x","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"56_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S0014-5793(98)00234-8","volume":"425","author":"A Merched","year":"1998","unstructured":"Merched A, Serot JM, Visvikis S, Aguillon D, Faure G, Siest G: Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer\u2019s patients: relation with the senile plaques and cytoskeleton biochemistry. FEBS Lett. 1998, 425 (2): 225-228. 10.1016\/S0014-5793(98)00234-8","journal-title":"FEBS Lett"},{"key":"56_CR17","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1468-1331.2009.02841.x","volume":"17","author":"K Schultz","year":"2010","unstructured":"Schultz K, Nilsson K, Nielsen JE, Lindquist SG, Hjermind LE, Andersen BB, Wallin A, Nilsson C, Petersen A: Transthyretin as a potential CSF biomarker for Alzheimer\u2019s disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors. Eur J Neurol. 2010, 17: 456-460. 10.1111\/j.1468-1331.2009.02841.x","journal-title":"Eur J Neurol"},{"issue":"4","key":"56_CR18","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1136\/jnnp.63.4.506","volume":"63","author":"JM Serot","year":"1997","unstructured":"Serot JM, Christmann D, Dubost T, Couturier M: Cerebrospinal fluid transthyretin: aging and late onset Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 1997, 63 (4): 506-508. 10.1136\/jnnp.63.4.506","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"56_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/jssc.200500377","volume":"29","author":"NH Heegaard","year":"2006","unstructured":"Heegaard NH, Hansen MZ, Sen JW, Christiansen M, Westermark P: Immunoaffinity chromatographic and immunoprecipitation methods combined with mass spectrometry for characterization of circulating transthyretin. J Sep Sci. 2006, 29 (3): 371-377. 10.1002\/jssc.200500377","journal-title":"J Sep Sci"},{"issue":"2","key":"56_CR20","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ymeth.2011.12.009","volume":"56","author":"K Poulsen","year":"2012","unstructured":"Poulsen K, Bahl JM, Tanassi JT, Simonsen AH, Heegaard NH: Characterization and stability of transthyretin isoforms in cerebrospinal fluid examined by immunoprecipitation and high-resolution mass spectrometry of intact protein. Methods. 2012, 56 (2): 284-292. 10.1016\/j.ymeth.2011.12.009","journal-title":"Methods"},{"issue":"1","key":"56_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cpet.2009.12.003","volume":"5","author":"RS Osorio","year":"2010","unstructured":"Osorio RS, Berti V, Mosconi L, Li Y, Glodzik L, De Santi S, de Leon MJ: Evaluation of early dementia (mild cognitive impairment). PET Clin. 2010, 5 (1): 15-31. 10.1016\/j.cpet.2009.12.003. 10.1016\/j.cpet.2009.12.003","journal-title":"PET Clin"},{"issue":"3","key":"56_CR22","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.clineuro.2004.10.011","volume":"107","author":"N Andreasen","year":"2005","unstructured":"Andreasen N, Blennow K: CSF biomarkers for mild cognitive impairment and early Alzheimer\u2019s disease. Clin Neurol Neurosurg. 2005, 107 (3): 165-173. 10.1016\/j.clineuro.2004.10.011","journal-title":"Clin Neurol Neurosurg"},{"issue":"3","key":"56_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1046\/j.1468-1331.1999.630279.x","volume":"6","author":"P Hogh","year":"1999","unstructured":"Hogh P, Waldemar G, Knudsen GM, Bruhn P, Mortensen H, Wildschiodtz G, Bech RA, Juhler M, Paulson OB: A multidisciplinary memory clinic in a neurological setting: diagnostic evaluation of 400 consecutive patients. Eur J Neurol. 1999, 6 (3): 279-288. 10.1046\/j.1468-1331.1999.630279.x","journal-title":"Eur J Neurol"},{"issue":"1","key":"56_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/01376517-200702000-00006","volume":"39","author":"K Thynne","year":"2007","unstructured":"Thynne K: Normal pressure hydrocephalus. J Neurosci Nurs. 2007, 39 (1): 27-32. 10.1097\/01376517-200702000-00006","journal-title":"J Neurosci Nurs"},{"key":"56_CR25","volume-title":"MMSE Mini-Mental State Examination. Clinical Guide","author":"MF Folstein","year":"2001","unstructured":"Folstein MF, Folstein SE, Fanjiang G: MMSE Mini-Mental State Examination. Clinical Guide. 2001, Psychological Assessment Resources, Inc,"},{"issue":"4","key":"56_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000209271","volume":"27","author":"J Stokholm","year":"2009","unstructured":"Stokholm J, Vogel A, Johannsen P, Waldemar G: Validation of the Danish Addenbrooke\u2019s cognitive examination as a screening test in a memory clinic. Dement Geriatr Cogn Disord. 2009, 27 (4): 361-365. 10.1159\/000209271","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"3","key":"56_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH: The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011, 7 (3): 263-269. 10.1016\/j.jalz.2011.03.005","journal-title":"Alzheimers Dement"},{"issue":"3","key":"56_CR28","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1001\/archneur.56.3.303","volume":"56","author":"RC Petersen","year":"1999","unstructured":"Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999, 56 (3): 303-308. 10.1001\/archneur.56.3.303","journal-title":"Arch Neurol"},{"issue":"3 Suppl","key":"56_CR29","first-page":"S4","volume":"57","author":"N Relkin","year":"2005","unstructured":"Relkin N, Marmarou A, Klinge P, Bergsneider M, Black PM: Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery. 2005, 57 (3 Suppl): S4-S16.","journal-title":"Neurosurgery"},{"issue":"12","key":"56_CR30","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1515\/CCLM.2006.258","volume":"44","author":"H Vanderstichele","year":"2006","unstructured":"Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, Ivanoiu A, Hampel H, Burger K, Parnetti L, Lanari A, Padovani A, DiLuca M, Blaser M, Olsson AO, Pottel H, Hulstaert F, Vanmechelen E: Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer\u2019s disease and dementia with Lewy bodies. Clin Chem Lab Med. 2006, 44 (12): 1472-1480.","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"56_CR31","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1212\/WNL.52.8.1555","volume":"52","author":"F Hulstaert","year":"1999","unstructured":"Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H: Improved discrimination of AD patients using beta-amyloid(1\u201342) and tau levels in CSF. Neurology. 1999, 52 (8): 1555-1562. 10.1212\/WNL.52.8.1555","journal-title":"Neurology"},{"key":"56_CR32","first-page":"Unit 13.6","volume":"Chapter 13","author":"RD Leduc","year":"2007","unstructured":"Leduc RD, Kelleher NL: Using ProSight PTM and related tools for targeted protein identification and characterization with high mass accuracy tandem MS data. Curr Protoc Bioinformatics. 2007, Chapter 13: Unit 13.6-","journal-title":"Curr Protoc Bioinformatics"},{"issue":"10","key":"56_CR33","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1021\/ac900243p","volume":"81","author":"BL Boys","year":"2009","unstructured":"Boys BL, Kuprowski MC, Noel JJ, Konermann L: Protein oxidative modifications during electrospray ionization: solution phase electrochemistry or corona discharge-induced radical attack?. Anal Chem. 2009, 81 (10): 4027-4034. 10.1021\/ac900243p","journal-title":"Anal Chem"},{"issue":"5","key":"56_CR34","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1021\/ac061743r","volume":"79","author":"M Chen","year":"2007","unstructured":"Chen M, Cook KD: Oxidation artifacts in the electrospray mass spectrometry of Abeta Peptide. Anal Chem. 2007, 79 (5): 2031-2036. 10.1021\/ac061743r","journal-title":"Anal Chem"},{"issue":"5","key":"56_CR35","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/S1044-0305(03)00128-4","volume":"14","author":"A Schmidt","year":"2003","unstructured":"Schmidt A, Karas M, Dulcks T: Effect of different solution flow rates on analyte ion signals in nano-ESI MS, or: when does ESI turn into nano-ESI?. J Am Soc Mass Spectrom. 2003, 14 (5): 492-500. 10.1016\/S1044-0305(03)00128-4","journal-title":"J Am Soc Mass Spectrom"},{"issue":"1","key":"56_CR36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JAD-2008-14102","volume":"14","author":"SF Gloeckner","year":"2008","unstructured":"Gloeckner SF, Meyne F, Wagner F, Heinemann U, Krasnianski A, Meissner B, Zerr I: Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J Alzheimers Dis. 2008, 14 (1): 17-25.","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"56_CR37","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jpsychires.2010.07.011","volume":"45","author":"B Ray","year":"2011","unstructured":"Ray B, Reyes PF, Lahiri DK: Biochemical studies in Normal Pressure Hydrocephalus (NPH) patients: change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Abeta) peptide and phospho-tau. J Psychiatr Res. 2011, 45 (4): 539-547. 10.1016\/j.jpsychires.2010.07.011","journal-title":"J Psychiatr Res"},{"issue":"2","key":"56_CR38","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1468-1331.2006.01593.x","volume":"14","author":"EN Kapaki","year":"2007","unstructured":"Kapaki EN, Paraskevas GP, Tzerakis NG, Sfagos C, Seretis A, Kararizou E, Vassilopoulos D: Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer\u2019s disease. Eur J Neurol. 2007, 14 (2): 168-173. 10.1111\/j.1468-1331.2006.01593.x","journal-title":"Eur J Neurol"},{"issue":"5","key":"56_CR39","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jalz.2011.01.003","volume":"7","author":"A Tarnaris","year":"2011","unstructured":"Tarnaris A, Toma AK, Pullen E, Chapman MD, Petzold A, Cipolotti L, Kitchen ND, Keir G, Lemieux L, Watkins LD: Cognitive, biochemical, and imaging profile of patients suffering from idiopathic normal pressure hydrocephalus. Alzheimers Dement. 2011, 7 (5): 501-508. 10.1016\/j.jalz.2011.01.003","journal-title":"Alzheimers Dement"},{"issue":"5","key":"56_CR40","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/j.1600-0404.2007.00890.x","volume":"116","author":"A Agren-Wilsson","year":"2007","unstructured":"Agren-Wilsson A, Lekman A, Sjoberg W, Rosengren L, Blennow K, Bergenheim AT, Malm J: CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand. 2007, 116 (5): 333-339. 10.1111\/j.1600-0404.2007.00890.x","journal-title":"Acta Neurol Scand"}],"container-title":["Clinical Proteomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1559-0275-11-12.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T03:21:40Z","timestamp":1630552900000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalproteomicsjournal.biomedcentral.com\/articles\/10.1186\/1559-0275-11-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,29]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["56"],"URL":"https:\/\/doi.org\/10.1186\/1559-0275-11-12","relation":{},"ISSN":["1542-6416","1559-0275"],"issn-type":[{"value":"1542-6416","type":"print"},{"value":"1559-0275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,29]]},"assertion":[{"value":"26 August 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"12"}}